Herui R. Yao
107 Yanjiang West Road
Guangzhou, 510120, China
Guangzhou, 510120, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 147 publications
Clinical efficacy and safety of a modified transurethral diode laser four-troughs vaporesection in treating benign prostatic hyperplasia
Journal: Zhonghua yi xue za zhi
Published: September 07, 2026
Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study.
Journal: Breast cancer research and treatment
Published: May 21, 2026
Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial.
Journal: Cancer research and treatment
Published: April 12, 2026
Comparison of Clinicopathological Features and Survival Between Distant Lymph Node Metastasis and Distant Micrometastasis in Breast Cancer.
Journal: Clinical breast cancer
Published: April 07, 2026
Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer.
Journal: Therapeutic advances in medical oncology
Published: March 28, 2026
A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody-drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours.
Journal: EBioMedicine
Published: January 13, 2026
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
Journal: The New England journal of medicine
Published: December 10, 2025
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 14, 2025
De-escalation of axillary surgery after neoadjuvant therapy in breast cancer: long-term outcomes of sentinel lymph node biopsy alone versus complete axillary lymph node dissection.
Journal: Therapeutic advances in medical oncology
Published: September 27, 2025
SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial.
Journal: Signal transduction and targeted therapy
Published: September 05, 2025
Last Updated: 09/26/2026